Navigation Links
Aging Population & Rising Incidence of Chronic Diseases to Drive the Global Mesenchymal Stem Cells Market, According to New Report by Global Industry Analysts, Inc.
Date:1/13/2014

San Jose, California (PRWEB) January 13, 2014

Follow us on LinkedIn – Stem Cells represent one of the most rapidly growing areas of biotechnology, and investors are currently injecting money into the development of stem cell therapies for a broad range of hard-to-treat diseases. The adult stem cells market is huge compared to cord blood and embryonic stem cell markets. Implementation of various governmental regulations is expected to drive growth in stem cell research over the coming years. The economic and medical potential of stem cell research is encouraging huge investments in the sector by governments, as well as pharmaceutical and biotechnology companies.

The use of human cells as clinical therapies for the treatment of various diseases has undergone a dramatic expansion in the last few years, thus leading to the development of a new branch in medical science – regenerative medicine. Regenerative medicine is a science that involves introduction of cells into the human body with the aim of replacing diseased or dying cells with healthy ones. A plethora of information pertaining to the biology and differentiation potential of Mesenchymal Stem Cells is available, and several thousands of publications have thrown light on the heterogenic nature of the MSC population, depending on species, donor and source tissue characteristics. Thus, MSCs represent one of the most promising systems for cell therapy due to their partial ability to ape embryonic stem cells, and other advantages associated with ethical implications, expandability, availability, and transplantability.

Mesenchymal Stem Cells, mainly found in the bone marrow, are multipotent stem cells that can differentiate into various cell types, including chondrocytes, osteoblasts, myocytes, beta-pancreatic islets cells, adipocytes, and even neuronal cells. In addition to their ability to differentiate into various cell types, MSCs are associated with a large number of benefits, such as easy acquisition and isolation, rapid ex vivo expansion, ease of autologous transplantation and superior paracrine function. MSCs thus represent a population of cells with potential to cure a wide range of degenerative and acute diseases and injuries.

Aging population and rise in age-related health ailments, especially those related to the heart and bone is driving demand for convenient, efficient and painless therapies. The ability of MSCs to regenerate and repair cartilages and bone tissues is being exploited for development of therapeutic procedures for various bone related diseases and injuries. MSCs are also being viewed as a potential substitute to knee replacement surgeries and other operative procedures such as those requiring correction of the knee meniscus. These therapies would be of special interest to ageing demographics, as MSC therapies help lower the risk of complications, pain and discomfort associated with conventional invasive surgical procedures.

As stated by the new market research report on Mesenchymal Stem Cells, the United States represents the largest market worldwide. Asia-Pacific represents the market with the highest growth potential. Growth in the region is led by growing healthcare spends, rising life expectancies and growing incidence of chronic diseases.

Key players covered in the report include Aastrom Biosciences Inc, Advanced Cell Technology Incorporated, Anterogen Co Ltd., Athersys Inc., Cell Applications Inc., Celprogen Inc., Cyagen Biosciences Inc., EMD Millipore Corporation, Genlantis Inc., K-Stecmcell Co Ltd., Life Technologies Corporation, Lonza Group, Medipost Co Ltd., Mesoblast Limited, Neuromics, NuVasive® Inc., Orthofix International N.V., Osiris Therapeutics Inc., Pharmicell Co Ltd., PromoCell GmbH, R&D Systems Inc., ScienCell Research Laboratories, Stemcell Technologies Inc., Stemedica Cell Technologies Inc., StemGenesis, Stempeutics Research Pvt Ltd., TiGenix NV, Trevigen Inc., and Vitro Biopharma, among others.

The research report titled "Mesenchymal Stem Cells (MSCs): A Global Strategic Business Report" announced by Global Industry Analysts Inc., provides a comprehensive review of the market, industry overview, trends, growth drivers, latest product launches and recent industry activity. The report provides market estimates and projections in US dollars for major geographic markets including the United States, Canada, Japan, Europe, Asia-Pacific, and Rest of World.

For more details about this comprehensive market research report, please visit –
http://www.strategyr.com/Mesenchymal_Stem_Cells_Market_Report.asp

About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes more than 1300 full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world's largest and reputed market research firms.

Global Industry Analysts, Inc.
Telephone: 408-528-9966
Fax: 408-528-9977
Email: press(at)StrategyR(dot)com
Web Site: http://www.StrategyR.com/

###

Read the full story at http://www.prweb.com/releases/mesenchymal_stem_cells/healthcare_industry/prweb11483334.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Latest Technologies for Life-saving Applications on the Program at SPIE Medical Imaging
2. Studies Show Pterostilbene Shows Promise for Anti-Aging and Maintaining Healthy Brain
3. Founders Fund Backs Nanotronics Imaging
4. The Houston Methodist Human Performance Lab Launches Innovative Study on Triathletes, Investigating the Effects of Aging and Training Variables on Triathlon Performance
5. Smart Imaging Technologies and InvitroCue Team Up to Bring Digital Pathology to Asia
6. New venue, new conference, new courses, new technologies for Electronic Imaging 2014
7. Scientists accelerate aging in stem cells to study age-related diseases like Parkinsons
8. Prova Education Announces Expansion of Its Nationwide Medical Education Series “From Guideline to Practice: Managing Challenging Cases in Primary Care”
9. MiMedx Announces Its Support Of New CMS Packaging Payment Policy For Skin Substitutes
10. Biomedical Research Foundation (BRF) Recruits Two Eminent Scientists --Pradeep Garg, Ph.D., And Sudha Garg, Ph.D. -- To Run Newly-Created Louisiana Center For Molecular Imaging And Therapy
11. New Survey Suggests Priobiotics Could be the Key to Encouraging More Patients to Complete a Course of Antibiotics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... ... regulatory and technical consulting, provides a free webinar on Performing Quality ... 13, 2016 at 12pm CT at no charge. , Incomplete investigations are still ...
(Date:6/23/2016)... 2016  Amgen (NASDAQ: AMGN ) today ... life sciences incubator to accelerate the development of ... space at QB3@953 was created to help high-potential life ... many early stage organizations - access to laboratory infrastructure. ... launched two "Amgen Golden Ticket" awards, providing each winner ...
(Date:6/22/2016)... 2016 Cell Applications, Inc. and StemoniX ... produce up to one billion human induced pluripotent ... week. These high-quality, consistent stem cells enable researchers ... spend more time doing meaningful, relevant research. This ... manufacturing process that produces affordable, reliable HiPSC for ...
(Date:6/22/2016)... , June 22, 2016  According to Kalorama ... generation sequencing (NGS) market include significant efforts in ... sequencers.  More accessible and affordable sequencers, say the ... demand for consumables including sample prep materials.  The ... for Sample Preparation for Next Generation Sequencing (NGS) ...
Breaking Biology Technology:
(Date:4/28/2016)... , April 28, 2016 First quarter 2016: ... up 966% compared with the first quarter of 2015 ... SEK 589.1 M (loss: 18.8) and the operating margin was 40% ... 0.32) Cash flow from operations was SEK 249.9 M ... revenue guidance is unchanged, SEK 7,000-8,500 M. The operating ...
(Date:4/15/2016)... CHICAGO , April 15, 2016  A ... companies make more accurate underwriting decisions in a ... offering timely, competitively priced and high-value life insurance ... health screenings. With Force Diagnostics, rapid ... and lifestyle data readings (blood pressure, weight, pulse, ...
(Date:3/31/2016)...   LegacyXChange, Inc. ... LegacyXChange is excited to release its first ... be launched online site for trading 100% guaranteed authentic ... also provide potential shareholders a sense of the value ... industry that is notorious for fraud. The video is ...
Breaking Biology News(10 mins):